Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $9

Benzinga Newsdesk www.benzinga.com Neutral 55.2%

Neg 0% Neu 55.2% Pos 0%

Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:RXST) with a Equal-Weight and lowers the price target from $11 to $9.